Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung

Lung Cancer

Volumn 99, Issue , 2016, Pages 117-119

  Semper, H ^a   Muehlberg, F ^b   Schulz Menger, J ^b   Allewelt, M ^a   Grohe C ^a  

^a Department of Respiratory Medicine   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Drug induced myocarditis; Immunotherapy; Nivolumab; PDL 1; Pulmonary squamous cell carcinoma

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CISPLATIN; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GADOLINIUM; NAVELBINE; NIVOLUMAB; PREDNISOLONE; PROGRAMMED DEATH 1 LIGAND 1; TROPONIN T; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; AORTA VALVE REGURGITATION; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER FATIGUE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; DRUG INDUCED DISEASE; DYSPNEA; ELECTROCARDIOGRAM; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART RIGHT BUNDLE BRANCH BLOCK; HOSPICE CARE; HOSPITAL ADMISSION; HUMAN; HYPOKINESIA; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; LIVER METASTASIS; LUNG ANGIOGRAPHY; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; PERICARDIAL EFFUSION; POOR GENERAL CONDITION; PRIORITY JOURNAL; RADIOTHERAPY DOSAGE; SINUS TACHYCARDIA; SQUAMOUS CELL LUNG CARCINOMA; ST SEGMENT DEPRESSION; THORAX PAIN; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE; CANCER STAGING; COMPLICATION; LUNG TUMOR; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; SQUAMOUS CELL CARCINOMA; X-RAY COMPUTED TOMOGRAPHY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CARCINOMA, SQUAMOUS CELL; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDITIS; NEOPLASM STAGING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84978821866     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.06.025     Document Type: Article

References (15)

1. [1] Dong, H., Strome, S.E., Salomao, D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8 (2002), 793–800.
2. [2] Iwai, Y., Ishida, M., Tanaka, Y., et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 99:19 (2002), 12293–12297.
3. [3] Topalian, S.L., Drake, C.G., Pardoll, D.M., Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24 (2012), 207–212.
4. [4] Rizvi, N.A., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 3 (2015), 257–265.
5. [5] Brahmer, J., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373:2 (2015), 123–135.
6. [6] Gettinger, S.N., et al. Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer. J. Clin. Oncol. 33 (2015), 2004–2012.
7. [7] Brahmer, J., et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
8. [8] Villadolid, J., Asim, A., Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl. Lung Cancer Res. 4:5 (2015), 560–575.
9. [9] Topalian, S.L., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32 (2014), 1020–1030.
10. [10] Wang, J., Okazaki, I.M., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int. Immunol. 22 (2010), 443–452.
11. [11] Läubli, H., et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J. Immunother. Cancer, 3, 2015, 11.
12. [12] Jordan, J.H., et al. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance. Circ. Cardiovasc. Imaging 7:November (6) (2014), 872–879.
13. [13] Fallah-Rad, N., et al. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J. Cardiovasc. Magn. Reson., 10, 2008, 5.
14. [14] Gulati, G., et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur. Heart J., 2016 (Feb 21 [Epub ahead of print]).
15. [15] Carbognin, L., et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of Programmed Death-Ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One, 6, 2015, e0130142.